Study S001986

Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Grade 1 Cancer of the Endometrium (WE-FiERCE)

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06073184
Acronym: WE-FiERCE
Study type: INTERVENTIONAL
Phase: PHASE2
Masking: NONE
Status: RECRUITING
Enrollment: 71
Start: 2026-09-17
Primary completion: 2029-02
Lead sponsor: GynOncTrials
Conditions: Endometrial Cancer; Atypical Hyperplasia; Fertility Perservation
Interventions: DRUG:Wegovy; DRUG:Mirena
Results posted: FALSE

Registered primary outcomes

Assessment of Complete Pathologic Response [48 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.